Abstract
Head and neck squamous cell carcinoma (HNSCC) is the 6th most common cancer worldwide and has a mortality rate of 50% despite surgery. The major risk factors associated with HNSCC are smoking, alcohol, and human papillomavirus (HPV). p53, a transcriptional factor, is the most commonly mutated protein in HNSCC and plays an important and early role in tumorigenesis. The chapter highlights the story of p53 in the progression and management of HNSCC. In particular, we address p53’s mutational landscape and its resultant phenotypic outcomes. In addition, p53 as a prognostic biomarker and predictive biomarker for clinical outcome is addressed. Finally, we discuss p53 as a druggable target in HNSCC patients. This chapter aims to expand the understanding of the role of p53 in HNSCC in order to improve management of HNSCC patients by providing them with a personalized and customizable treatment plan.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B, Solari A, Bobisse S, Rondina MB, Guzzardo V, Parenti AR, Rosato A, Bicciato S, Balmain A, Piccolo S (2009) A mutant-p53/smad complex opposes p63 to empower TGFβ-induced metastasis. Cell 137(1):87–98. doi:10.1016/j.cell.2009.01.039
Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, Fakhry C, Xie T-X, Zhang J, Wang J, Zhang N, El-Naggar AK, Jasser SA, Weinstein JN, Treviño L, Drummond JA, Muzny DM, Wu Y, Wood LD, Hruban RH, Westra WH, Koch WM, Califano JA, Gibbs RA, Sidransky D, Vogelstein B, Velculescu VE, Papadopoulos N, Wheeler DA, Kinzler KW, Myers JN (2011) Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333(6046):1154–1157. doi:10.1126/science.1206923
Aloni-Grinstein R, Schwartz D, Rotter V (1995) Accumulation of wild-type p53 protein upon gamma-irradiation induces a G2 arrest-dependent immunoglobulin kappa light chain gene expression. EMBO J 14(7):1392–1401
Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363(1):24–35. doi:10.1056/NEJMoa0912217
Argiris A, Karamouzis MV, Raben D, Ferris RL (2008) Head and neck cancer. Lancet (London, England) 371(9625):1695–1709. doi:10.1016/s0140-6736(08)60728-x
Balz V, Scheckenbach K, Götte K, Bockmühl U, Petersen I, Bier H (2003) Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2–11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens. Cancer Res 63(6):1188–1191
Berkers CR, Maddocks OD, Cheung EC, Mor I, Vousden KH (2013) Metabolic regulation by p53 family members. Cell Metab 18(5):617–633. doi:10.1016/j.cmet.2013.06.019
Berns K, Hijmans EM, Mullenders J, Brummelkamp TR, Velds A, Heimerikx M, Kerkhoven RM, Madiredjo M, Nijkamp W, Weigelt B, Agami R, Ge W, Cavet G, Linsley PS, Beijersbergen RL, Bernards R (2004) A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428(6981):431–437. doi:10.1038/nature02371
Bond GL, Hu W, Levine A (2005) A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res 65(13):5481–5484. doi:10.1158/0008-5472.CAN-05-0825
Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH (2003) A genetic explanation of Slaughter’s concept of field cancerization: evidence and clinical implications. Cancer Res 63(8):1727–1730
Braakhuis BJ, Snijders PJ, Keune WJ, Meijer CJ, Ruijter-Schippers HJ, Leemans CR, Brakenhoff RH (2004) Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst 96(13):998–1006
Bradford CR, Zhu S, Ogawa H, Ogawa T, Ubell M, Narayan A, Johnson G, Wolf GT, Fisher SG, Carey TE (2003) P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck 25(8):654–661. doi:10.1002/hed.10274
Brosh R, Rotter V (2009) When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 9(10):701–713. doi:10.1038/nrc2693
Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP (2009) Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 9(12):862–873. doi:10.1038/nrc2763
Bullock AN, Henckel J, Fersht AR (2000) Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene 19(10):1245–1256. doi:10.1038/sj.onc.1203434
Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG, Selivanova G (2002) Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 8(3):282–288. doi:10.1038/nm0302-282
Cabelguenne A, Blons H, de Waziers I, Carnot F, Houllier AM, Soussi T, Brasnu D, Beaune P, Laccourreye O, Laurent-Puig P (2000) p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J Clin Oncol Off J Am Soc Clin Oncol 18(7):1465–1473
Caicedo-Granados E, Lin R, Fujisawa C, Yueh B, Sangwan V, Saluja A (2014) Wild-type p53 reactivation by small-molecule Minnelide™ in human papillomavirus (HPV)-positive head and neck squamous cell carcinoma. Oral Oncol 50(12):1149–1156. doi:10.1016/j.oraloncology.2014.09.013
Chuang HC, Yang LP, Fitzgerald AL, Osman A, Woo SH, Myers JN, Skinner HD (2014) The p53-reactivating small molecule RITA induces senescence in head and neck cancer cells. PLoS ONE 9(8):e104821. doi:10.1371/journal.pone.0104821
Cimpean AM, Balica RA, Doros IC, Balica NC, Gaje PN, Popovici RA, Raica M (2016) Epidermal growth factor receptor (EGFR) and keratin 5 (K5): versatile keyplayers defining prognostic and therapeutic sub-classes of head and neck squamous cell carcinomas. Cancer Genom Proteom 13(1):75–81
Clayman GL, el-Naggar AK, Lippman SM, Henderson YC, Frederick M, Merritt JA, Zumstein LA, Timmons TM, Liu TJ, Ginsberg L, Roth JA, Hong WK, Bruso P, Goepfert H (1998) Adenovirus-mediated p 53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol 16 (6):2221–2232
Csuka O, RemenÁr É, Koronczay K, Doleschall Z, NÉmeth G (1997) Predictive value of p53, Bcl2 and bax in the radiotherapy of head and neck cancer. Pathol Oncol Res 3(3):204–210. doi:10.1007/bf02899922
Davison TS, Vagner C, Kaghad M, Ayed A, Caput D, Arrowsmith CH (1999) p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53. J Biol Chem 274(26):18709–18714
Di Agostino S, Cortese G, Monti O, Dell’Orso S, Sacchi A, Eisenstein M, Citro G, Strano S, Blandino G (2008) The disruption of the protein complex mutantp53/p 73 increases selectively the response of tumor cells to anticancer drugs. Cell Cycle (Georgetown, Tex) 7(21):3440–3447. doi:10.4161/cc.7.21.6995
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12):2893–2917. doi:10.1002/ijc.25516
Foster BA, Coffey HA, Morin MJ, Rastinejad F (1999) Pharmacological rescue of mutant p53 conformation and function. Science 286(5449):2507–2510
Freed-Pastor WA, Prives C (2012) Mutant p53: one name, many proteins. Genes Dev 26(12):1268–1286. doi:10.1101/gad.190678.112
Freed-Pastor WA, Mizuno H, Zhao X, Langerod A, Moon SH, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li W, Polotskaia A, Bissell MJ, Osborne TF, Tian B, Lowe SW, Silva JM, Borresen-Dale AL, Levine AJ, Bargonetti J, Prives C (2012) Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 148(1–2):244–258. doi:10.1016/j.cell.2011.12.017
Ganly I, Kirn D, Eckhardt G, Rodriguez GI, Soutar DS, Otto R, Robertson AG, Park O, Gulley ML, Heise C, Von Hoff DD, Kaye SB (2000) A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res Off J Am Assoc Cancer Res 6(3):798–806
Girardini JE, Napoli M, Piazza S, Rustighi A, Marotta C, Radaelli E, Capaci V, Jordan L, Quinlan P, Thompson A, Mano M, Rosato A, Crook T, Scanziani E, Means AR, Lozano G, Schneider C, Del Sal G (2011) A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell 20(1):79–91. doi:10.1016/j.ccr.2011.06.004
Gottlieb E, Haffner R, von Ruden T, Wagner EF, Oren M (1994) Down-regulation of wild-type p53 activity interferes with apoptosis of IL-3-dependent hematopoietic cells following IL-3 withdrawal. EMBO J 13(6):1368–1374
Hainaut P, Hollstein M (2000) p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 77:81–137
Huang J, Perez-Burgos L, Placek BJ, Sengupta R, Richter M, Dorsey JA, Kubicek S, Opravil S, Jenuwein T, Berger SL (2006) Repression of p 53 activity by Smyd2-mediated methylation. Nature 444(7119):629–632. doi:http://www.nature.com/nature/journal/v444/n7119/suppinfo/nature05287_S1.html
Hussain SP, Harris CC (1998) Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res 58(18):4023–4037
Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M, Pramanik A, Selivanova G (2004) Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 10(12):1321–1328. doi:10.1038/nm1146
Iwakuma T, Parrales A (2015) Targeting oncogenic mutant p 53 for cancer therapy. Front Oncol 5. doi:10.3389/fonc.2015.00288
Katsonis P, Lichtarge O (2014) A formal perturbation equation between genotype and phenotype determines the evolutionary action of protein-coding variations on fitness. Genome Res 24(12):2050–2058. doi:10.1101/gr.176214.114
Klussmann JP, Weissenborn SJ, Wieland U, Dries V, Kolligs J, Jungehuelsing M, Eckel HE, Dienes HP, Pfister HJ, Fuchs PG (2001) Prevalence, distribution, and viral load of human papillomavirus 16 DNA in tonsillar carcinomas. Cancer 92(11):2875–2884
Lamont JP, Nemunaitis J, Kuhn JA, Landers SA, McCarty TM (2000) A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience). Ann Surg Oncol 7(8):588–592
Lane DP (1992) Cancer. p53, guardian of the genome. Nature 358(6381):15–16. doi:10.1038/358015a0
Lang GA, Iwakuma T, Suh Y-A, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, El-Naggar AK, Lozano G (2004) Gain of Function of a p53 Hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119(6):861–872. doi:10.1016/j.cell.2004.11.006
Leemans CR, Braakhuis BJM, Brakenhoff RH (2011) The molecular biology of head and neck cancer. Nat Rev Cancer 11(1):9–22
Levine AJ, Wu MC, Chang A, Silver A, Attiyeh EF, Lin J, Epstein CB (1995) The spectrum of mutations at the p53 locus. Ann N Y Acad Sci 768(1):111–128. doi:10.1111/j.1749-6632.1995.tb12115.x
Li Y, Prives C (2007) Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? Oncogene 26(15):2220–2225
Li Y, Li LJ, Zhang ST, Wang LJ, Zhang Z, Gao N, Zhang YY, Chen QM (2009) In vitro and clinical studies of gene therapy with recombinant human adenovirus-p53 injection for oral leukoplakia. Clin Cancer Res Off J Am Assoc Cancer Res 15(21):6724–6731. doi:10.1158/1078-0432.ccr-09-1296
Linares LK, Hengstermann A, Ciechanover A, Muller S, Scheffner M (2003) HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Proc Natl Acad Sci U S A 100(21):12009–12014. doi:10.1073/pnas.2030930100
Liu TJ, el-Naggar AK, McDonnell TJ, Steck KD, Wang M, Taylor DL, Clayman GL (1995) Apoptosis induction mediated by wild-type p 53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. Cancer Res 55(14):3117–3122
Liu K, Ling S, Lin WC (2011) TopBP1 mediates mutant p53 gain of function through NF-Y and p63/p73. Mol Cell Biol 31(22):4464–4481. doi:10.1128/mcb.05574-11
Marur S, D’Souza G, Westra WH, Forastiere AA (2010) HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 11(8):781–789. doi:10.1016/s1470-2045(10)70017-6
Milner J, Medcalf EA (1991) Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 65(5):765–774. doi:10.1016/0092-8674(91)90384-B
Muller PAJ, Vousden KH (2013) p53 mutations in cancer. Nat Cell Biol 15(1):2–8
Muller PAJ, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S, Lukashchuk N, Gillespie DA, Ludwig RL, Gosselin P, Cromer A, Brugge JS, Sansom OJ, Norman JC, Vousden KH (2009) Mutant p53 drives invasion by promoting integrin recycling. Cell 139(7):1327–1341. doi:10.1016/j.cell.2009.11.026
Nemunaitis J, Nemunaitis J (2011) Head and neck cancer: response to p53-based therapeutics. Head Neck 33(1):131–134. doi:10.1002/hed.21364
Nemunaitis J, Cunningham C, Buchanan A, Blackburn A, Edelman G, Maples P, Netto G, Tong A, Randlev B, Olson S, Kirn D (2001a) Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther 8(10):746–759. doi:10.1038/sj.gt.3301424
Nemunaitis J, Khuri F, Ganly I, Arseneau J, Posner M, Vokes E, Kuhn J, McCarty T, Landers S, Blackburn A, Romel L, Randlev B, Kaye S, Kirn D (2001b) Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol Off J Am Soc Clin Oncol 19(2):289–298
Neskey DM, Osman AA, Ow TJ, Katsonis P, McDonald T, Hicks SC, Hsu T-K, Pickering CR, Ward A, Patel A, Yordy JS, Skinner HD, Giri U, Sano D, Story MD, Beadle BM, El-Naggar AK, Kies MS, William WN, Caulin C, Frederick M, Kimmel M, Myers JN, Lichtarge O (2015) Evolutionary action score of TP53 identifies high-risk mutations associated with decreased survival and increased distant metastases in head and neck cancer. Cancer Res 75(7):1527–1536. doi:10.1158/0008-5472.can-14-2735
Ohnishi K, Ota I, Takahashi A, Ohnishi T (2000) Glycerol restores p53-dependent radiosensitivity of human head and neck cancer cells bearing mutant p53. Br J Cancer 83(12):1735–1739. doi:10.1054/bjoc.2000.1511
Ohnishi T, Ohnishi K, Takahashi A (2002) Glycerol restores heat-induced p53-dependent apoptosis of human glioblastoma cells bearing mutant p53. BMC Biotechnol 2:6
Ohtomo-Oda R, Komatsu S, Mori T, Sekine S, Hirajima S, Yoshimoto S, Kanai Y, Otsuji E, Ikeda E, Tsuda H (2016) SMYD2 overexpression is associated with tumor cell proliferation and a worse outcome in human papillomavirus–unrelated nonmultiple head and neck carcinomas. Hum Pathol 49:145–155. doi:10.1016/j.humpath.2015.08.025
Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T (2004) Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119(6):847–860. doi:10.1016/j.cell.2004.11.004
Osman AA, Neskey DM, Katsonis P, Patel AA, Ward AM, Hsu T-K, Hicks SC, McDonald TO, Ow TJ, Alves MO, Pickering CR, Skinner HD, Zhao M, Sturgis EM, Kies MS, El-Naggar A, Perrone F, Licitra L, Bossi P, Kimmel M, Frederick MJ, Lichtarge O, Myers JN (2015) Evolutionary action score of TP53 coding variants is predictive of platinum response in head and neck cancer patients. Cancer Res 75(7):1205–1215. doi:10.1158/0008-5472.can-14-2729
Patel D, Huang SM, Baglia LA, McCance DJ (1999) The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO J 18(18):5061–5072. doi:10.1093/emboj/18.18.5061
Pearson S, Jia H, Kandachi K (2004) China approves first gene therapy. Nat Biotechnol 22(1):3–4. doi:10.1038/nbt0104-3
Perri F, Pacelli R, Della Vittoria Scarpati G, Cella L, Giuliano M, Caponigro F, Pepe S (2015) Radioresistance in head and neck squamous cell carcinoma: biological bases and therapeutic implications. Head Neck 37(5):763–770. doi:10.1002/hed.23837
Perrone F, Bossi P, Cortelazzi B, Locati L, Quattrone P, Pierotti MA, Pilotti S, Licitra L (2010) TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol 28(5):761–766. doi:10.1200/jco.2009.22.4170
Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA, Ridge JA, Goodwin J, Kenady D, Saunders J, Westra W, Sidransky D, Koch WM (2007) TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 357(25):2552–2561. doi:10.1056/NEJMoa073770
Rippin TM, Bykov VJ, Freund SM, Selivanova G, Wiman KG, Fersht AR (2002) Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene 21(14):2119–2129. doi:10.1038/sj.onc.1205362
Roh JL, Kang SK, Minn I, Califano JA, Sidransky D, Koch WM (2011) p53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma. Oral Oncol 47(1):8–15. doi:10.1016/j.oraloncology.2010.10.011
Sankala H, Vaughan C, Wang J, Deb S, Graves PR (2011) Upregulation of the mitochondrial transport protein, Tim50, by mutant p53 contributes to cell growth and chemoresistance. Arch Biochem Biophys 512(1):52–60. doi:10.1016/j.abb.2011.05.005
Scheffner M, Huibregtse JM, Vierstra RD, Howley PM (1993) The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75(3):495–505. doi:10.1016/0092-8674(93)90384-3
Sigal A, Rotter V (2000) Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 60(24):6788–6793
Skinner HD, Sandulache VC, Ow TJ, Meyn RE, Yordy JS, Beadle BM, Fitzgerald AL, Giri U, Ang KK, Myers JN (2012) TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res Off J Am Assoc Cancer Res 18(1):290–300. doi:10.1158/1078-0432.ccr-11-2260
Smeets SJ, van der Plas M, Schaaij-Visser TB, van Veen EA, van Meerloo J, Braakhuis BJ, Steenbergen RD, Brakenhoff RH (2011) Immortalization of oral keratinocytes by functional inactivation of the p53 and pRb pathways. Int J Cancer 128(7):1596–1605. doi:10.1002/ijc.25474
Song H, Hollstein M, Xu Y (2007) p 53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol 9(5):573–580. doi:http://www.nature.com/ncb/journal/v9/n5/suppinfo/ncb1571_S1.html
Strano S, Dell’Orso S, Di Agostino S, Fontemaggi G, Sacchi A, Blandino G (2007) Mutant p53: an oncogenic transcription factor. Oncogene 26(15):2212–2219
Sturgis EM, Cinciripini PM (2007) Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer 110(7):1429–1435. doi:10.1002/cncr.22963
Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K (2009) Modulation of microRNA processing by p53. Nature 460(7254):529–533. doi:10.1038/nature08199
Szentkúti G, Dános K, Brauswetter D, Kiszner G, Krenács T, Csákó L, Répássy G, Tamás L (2015) Correlations between prognosis and regional biomarker profiles in head and neck squamous cell carcinomas. Pathol Oncol Res 21(3):643–650. doi:10.1007/s12253-014-9869-4
Takimoto R, Wang W, Dicker DT, Rastinejad F, Lyssikatos J, el-Deiry WS (2002) The mutant p 53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol Ther 1(1):47–55
Tandon S, Tudur-Smith C, Riley RD, Boyd MT, Jones TM (2010) A systematic review of p53 as a prognostic factor of survival in squamous cell carcinoma of the four main anatomical subsites of the head and neck. Cancer Epidemiol Biomarkers Prev 19(2):574–587. doi:10.1158/1055-9965.epi-09-0981 (A publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology)
Tanner S, Barberis A (2004) CP-31398, a putative p53-stabilizing molecule tested in mammalian cells and in yeast for its effects on p53 transcriptional activity. J Negat Results Biomed 3:5. doi:10.1186/1477-5751-3-5
Tassone P, Old M, Teknos TN, Pan Q (2013) p53-based therapeutics for head and neck squamous cell carcinoma. Oral Oncol 49(8):733–737. doi:10.1016/j.oraloncology.2013.03.447
The Cancer Genome Atlas N (2015) Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517(7536):576–582. doi:10.1038/nature14129. http://www.nature.com/nature/journal/v517/n7536/abs/nature14129.html-supplementary-information
Valenti F, Ganci F, Fontemaggi G, Sacconi A, Strano S, Blandino G, Di Agostino S (2015) Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression. Oncotarget 6(8):5547–5566. doi:10.18632/oncotarget.2587
Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303(5659):844–848. doi:10.1126/science.1092472
Vousden KH, Lane DP (2007) p53 in health and disease. Nat Rev Mol Cell Biol 8(4):275–283. doi:10.1038/nrm2147
Vousden KH, Lu X (2002) Live or let die: the cell’s response to p53. Nat Rev Cancer 2(8):594–604
Wang YV, Leblanc M, Wade M, Jochemsen AG, Wahl GM (2009) Increased radioresistance and accelerated B cell lymphomas in mice with Mdmx mutations that prevent modifications by DNA-damage-activated kinases. Cancer Cell 16(1):33–43. doi:10.1016/j.ccr.2009.05.008
Wichmann G, Rosolowski M, Krohn K, Kreuz M, Boehm A, Reiche A, Scharrer U, Halama D, Bertolini J, Bauer U, Holzinger D, Pawlita M, Hess J, Engel C, Hasenclever D, Scholz M, Ahnert P, Kirsten H, Hemprich A, Wittekind C, Herbarth O, Horn F, Dietz A, Loeffler M (2015) The role of HPV RNA transcription, immune response-related gene expression and disruptive TP53 mutations in diagnostic and prognostic profiling of head and neck cancer. Int J Cancer 137(12):2846–2857. doi:10.1002/ijc.29649
Wiest T, Schwarz E, Enders C, Flechtenmacher C, Bosch FX (2002) Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRB cell cycle control. Oncogene 21(10):1510–1517. doi:10.1038/sj/onc/1205214
Xie X, Piao L, Bullock BN, Smith A, Su T, Zhang M, Teknos TN, Arora PS, Pan Q (2014) Targeting HPV16 E6-p300 interaction reactivates p53 and inhibits the tumorigenicity of HPV-positive head and neck squamous cell carcinoma. Oncogene 33(8):1037–1046. doi:10.1038/onc.2013.25
Yoo GH, Piechocki MP, Oliver J, Lonardo F, Zumstein L, Lin HS, Kim H, Shibuya TY, Shehadeh N, Ensley JF (2004) Enhancement of Ad-p53 therapy with docetaxel in head and neck cancer. Laryngoscope 114(11):1871–1879. doi:10.1097/01.mlg.0000147914.51239.ed
Yoo GH, Moon J, Leblanc M, Lonardo F, Urba S, Kim H, Hanna E, Tsue T, Valentino J, Ensley J, Wolf G (2009) A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p 53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: report of the Southwest Oncology Group. Arch Otolaryngol Head Neck Surg 135(9):869–874. doi:10.1001/archoto.2009.122
Yu J, Zhang L (2003) No PUMA, no death: implications for p53-dependent apoptosis. Cancer Cell 4(4):248–249
Zhang Y, Xiong Y (2001) Control of p53 ubiquitination and nuclear export by MDM2 and ARF. Cell Growth Differ 12(4):175–186
Zhang S, Li Y, Li L, Zhang Y, Gao N, Zhang Z, Zhao H (2009) Phase i study of repeated intraepithelial delivery of adenoviral p53 in patients with dysplastic oral leukoplakia. J Oral Maxillofac Surg 67(5):1074–1082. doi:10.1016/j.joms.2008.06.079
Zhao CY, Grinkevich VV, Nikulenkov F, Bao W, Selivanova G (2010) Rescue of the apoptotic-inducing function of mutant p 53 by small molecule RITA. Cell Cycle (Georgetown, Tex) 9(9):1847–1855. doi:10.4161/cc.9.9.11545
Zhou G, Liu Z, Myers JN (2016) TP53 mutations in head and neck squamous cell carcinoma and their impact on disease progression and treatment response. J Cell Biochem. doi:10.1002/jcb.25592
Ziemann F, Arenz A, Preising S, Wittekindt C, Klussmann JP, Engenhart-Cabillic R, Wittig A (2015) Increased sensitivity of HPV-positive head and neck cancer cell lines to x-irradiation ± Cisplatin due to decreased expression of E6 and E7 oncoproteins and enhanced apoptosis. Am J Cancer Res 5(3):1017–1031
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Philips, R., Pan, Q. (2017). p53 in Head and Neck Squamous Cell Carcinoma. In: Warnakulasuriya, S., Khan, Z. (eds) Squamous cell Carcinoma. Springer, Dordrecht. https://doi.org/10.1007/978-94-024-1084-6_5
Download citation
DOI: https://doi.org/10.1007/978-94-024-1084-6_5
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-024-1083-9
Online ISBN: 978-94-024-1084-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)